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ORIGINAL ARTICLE
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Abstract
Objective: This randomized controlled trial aimed to compare the efficacy and safety of insulin
detemir (IDet) with neutral protamine Hagedorn (NPH), both with insulin aspart, in pregnant
women with type 1 diabetes. The perinatal and obstetric pregnancy outcomes are presented.
Methods: Subjects were randomized to IDet (n¼ 152) or NPH (n¼ 158) 12 months before
pregnancy or at 8–12 gestational weeks.
Results: For IDet and NPH, there were 128 and 136 live births, 11 and 9 early fetal losses, and
two and one perinatal deaths, respectively. Gestational age at delivery was greater for children
from the IDet arm than the NPH arm (treatment difference: 0.49 weeks [95% CI 0.11;0.88],
p¼ 0.012, linear regression). Sixteen children had a malformation (IDet: n¼ 8/142, 5.6%; NPH:
n¼ 8/145, 5.5%). The incidence of adverse events was similar between treatments.
Conclusion: IDet is as well tolerated as NPH as regards perinatal outcomes in pregnant women
with type 1 diabetes and no safety issues were identified.
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Introduction
Pregnancy in women with type 1 diabetes is associated with
an increase in adverse maternal, fetal and perinatal outcomes,
such as spontaneous abortions, congenital malformations,
preterm labor and macrosomia, compared with the general
population [1–3]. Several studies have confirmed that poor
glycemic control in women with either gestational, type 1 or
type 2 diabetes during pregnancy is associated with poor
pregnancy outcomes [1,4–7]. In particular, poor glycemic
control prior to or at the time of conception is associated with
increased rates of adverse maternal and perinatal outcomes
[2,5,6].
However, optimizing glycemic control, glycated hemoglo-
bin [A1C]57% [553 mmol/mol], does not guarantee a normal
outcome, as highlighted in the UK Confidential Enquiry into
Maternal and Child Health (CEMACH) study, in which 25%
of women whose baby had an anomaly had achieved A1C
57% [553 mmol/mol] by 13 weeks’ gestation [3,8,9]. Several
studies have shown that focusing on A1C levels is insufficient
to ensure that glucose concentrations are well controlled.
Instead, frequent daily monitoring of capillary glucose
concentrations is necessary to limit hyper- and hypoglycemic
excursions, as a single day of poor glycemic control during
the first trimester could negatively impact organogenesis [7].
Outside of pregnancy, short and long-acting insulin
analogs have been shown to result in better glycemic control
with less hypoglycemia than human insulins in subjects with
diabetes [10–13]. Recently, a randomized trial showed similar
benefits with short-acting analogs in pregnancy complicated
by type 1 diabetes [14]. In contrast, few studies have
examined the efficacy and safety of long-acting analogs in
women with type 1 diabetes during pregnancy, despite their
increasing use in this subject group. Consequently, basal
insulin analogs have been used off-label [15]. Only one
randomized controlled trial, described here, has investigated
a basal analog, comparing insulin detemir (IDet) with
neutral protamine Hagedorn (NPH), both in combination
with insulin aspart (IAsp), in pregnant women with type 1
diabetes [16].
IDet is an insulin analog that has a consistent pharmaco-
kinetic/pharmacodynamic profile, with lower intra-subject
variability in terms of glucose-lowering effect compared with
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either NPH or insulin glargine in subjects with type 1 or
type 2 diabetes [17,18]. Studies have shown that IDet provides
similar glycemic control, but with lower rates of hypogly-
cemia and less weight gain, than NPH insulin in non-pregnant
subjects with type 1 or type 2 diabetes [13,19–24].
The aim of this study was to compare the efficacy and
safety of IDet with NPH in pregnant women with type 1
diabetes. This manuscript presents the primary data on
perinatal and obstetric pregnancy outcomes. Data on glycemic
control, maternal hypoglycemia and maternal safety have
been reported separately [16].
Methods
Trial design and interventions
This was a randomized, open-label, multinational, parallel-
group trial comparing the safety and efficacy of IDet with
NPH insulin, both used in combination with prandial IAsp
in a basal–bolus regimen in pregnant women with type 1
diabetes. This trial was conducted at 79 sites in 17 countries
between May 2007 and August 2010. The trial is registered as
ClinicalTrials.gov number NCT00474045. The trial was
conducted in accordance with the Declaration of Helsinki
and International Conference on Harmonisation Good
Clinical Practice Guidelines, and was approved by respective
ethics committees and health authorities according to local
regulations. International review board approval was obtained
prior to the start of the trial for each trial center. Written
informed consent was obtained from the subjects prior to trial
entry or any trial-related activities.
Women (18 years of age) with type 1 diabetes treated
with insulin (any regimen) for at least 12 months who were
either planning to become pregnant (screening A1C 9.0%
[75 mmol/mol]; A1C 8.0% [64 mmol/mol] at confirm-
ation of pregnancy) or were already pregnant with a singleton
pregnancy at gestational age (GA) 8–12 weeks (A1C 8.0%
[64 mmol/mol] at pregnancy confirmation) were eligible
for inclusion. Subjects with impaired hepatic or renal
function, uncontrolled hypertension (systolic blood pressure
140 mmHg and/or diastolic blood pressure 90 mmHg),
undergoing medical infertility treatment, or who had been
previously randomized in this trial were excluded.
Eligible subjects were randomized 1:1 to receive either IDet
(100 U/mL; Novo Nordisk, Bagsvaerd, Denmark) or NPH
(100 U/mL; Novo Nordisk, Bagsvaerd, Denmark), both in
combination with prandial IAsp (100 U/mL; Novo Nordisk,
Bagsvaerd, Denmark) in a basal–bolus regimen. The subjects
were stratified according to pregnancy status. Subjects
received the trial drug from randomization until termination/
6 weeks post-delivery. An open-label trial design was chosen
due to the differing appearances of the two treatments.
IDet or NPH was administered subcutaneously at the same
time and with the same frequency as the basal insulin that
was given prior to randomization. IAsp was administered
0–15 min before each main meal. Basal insulin doses were
titrated according to fasting and pre-dinner plasma glucose
(PG) values of 72–108 mg/dL (4.0–6.0 mmol/L). The bolus
insulin doses were titrated according to preprandial values of
72–108 mg/dL (4.0–6.0 mmol/L) and 2-h post-prandial PG
values of5126 mg/dL (57.0 mmol/L).
Assessments and endpoints
Subjects pregnant at randomization (at 8–12 gestational
weeks [GWs]) had the first trial visit at this point and
subsequent visits at 14, 24 and 36 GWs, at delivery/
termination, and at 6 weeks post-delivery. Subjects not
pregnant at randomization had visits every 3 months until
conception and then followed the same visit schedule as
detailed above. Non-pregnant subjects who did not reach A1C
8.0% [64 mmol/mol] after 9 months were withdrawn,
as were subjects who did not conceive within 12 months
of randomization or who had A1C48.0% [464 mmol/mol]
at confirmation of pregnancy. Pregnancy outcome is com-
prised of three main categories: fetal death, termination of
pregnancy and live birth.
The primary endpoint was A1C at 36 GWs as an indicator
of glycemic control. Secondary perinatal and obstetric
pregnancy safety endpoints included: a composite pregnancy
outcome, GA at delivery, small/large (510th or 490th
percentile) for GA, birth weight, macrosomia (more than
4000 g), live births, early fetal death, perinatal mortality,
neonatal mortality and induced abortions, neonatal hypogly-
cemia, congenital malformations, preterm delivery, pre-
eclampsia and adverse events (AEs). AEs were recorded for
the fetus/child until 6 weeks after birth. Maternal AEs were
recorded from first trial-related activity until 6 weeks after
giving birth. A serious AE included death of the fetus/neonate
(miscarriage, stillbirth or neonatal death) and any congenital
malformation. A severe AE was defined as an event that
considerably interfered with the subject’s daily activities.
The composite pregnancy outcome included at least one of
the following:
 Live-born infants with a birth weight 510th or 490th
percentile for GA and sex, according to local practice;
 Preterm delivery (delivery537 completed GWs);
 Early fetal death (522 completed GWs);
 Perinatal mortality (death of fetus/infant between 22
completed GWs and51 completed week after delivery);
 Neonatal mortality (postpartum death after 7 completed
days and before 28 completed days after delivery);
 Presence of major malformations.
Congenital malformations, defined as a morphological
defect of an organ or multiple organs of the body resulting
from an intrinsically abnormal developmental process, were
observed at gross examination either before birth (by
ultrasound) or after delivery. These malformations were
classified further as either major (a life-threatening structural
anomaly or one likely to cause significant impairment of
health or functional capacity) or minor (relatively frequent
structural anomaly not likely to cause any medical or
cosmetic problems) malformations, and described using the
Medical Dictionary for Regulatory Activities (MedDRA)
preferred terms. An appointed specialist performed a blinded
(including to treatment assignment) review of all serious AEs
for the identification of malformations. Due to the clinical
importance of congenital malformations, the serious AE data
were blinded and evaluated post hoc (after the primary
analysis) by a second specialist. Both specialists identified
malformations after a similar period of postnatal follow-up.
Both classifications were subsequently reviewed and
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approved by the European Medicines Agency and are
included here. Congenital malformations were evaluated by
randomized treatment and also by treatment during organo-
genesis (post hoc; after the primary analysis). Organogenesis
was defined as the period from 3 GWs until 8 GWs.
Neonatal hypoglycemia was defined as a PG level 31 mg/
dL (1.7 mmol/L) during the first 24 h after birth or a PG
level 45 mg/dL (2.5 mmol/L) between 24 and 48 hours
after birth.
Statistical analyses
The sample size was calculated as described in Mathiesen et al.
[16]. The trial was powered to show non-inferiority for A1C at
36 GWs (non-inferiority margin of 0.4%) for IDet compared
with NPH, and 120 subjects were planned to complete the trial
in each treatment group. The trial was not powered to detect a
difference between IDet and NPH in regards to the other
perinatal and obstetric pregnancy safety endpoints listed above.
The safety outcomes reported here were evaluated in the
safety analysis set for pregnant subjects (SASPregnant)
(exposed subjects who were pregnant during the trial). The
SASPregnant analysis set contained data from two subgroups of
pregnant women: subjects who were pregnant at randomiza-
tion and subjects who became pregnant after randomization.
Preterm delivery, live births, large for GA, neonatal hypo-
glycemia within 24 hours of delivery, macrosomia, pre-
eclampsia (all post hoc) and the composite pregnancy
outcome were analyzed using a logistic regression model
with treatment and pregnancy status at randomization as
factors. Birth weight and GA at delivery (both post hoc) were
analyzed using a linear regression model with treatment,
country and pregnancy status at randomization as factors. In
accordance with the intention-to-treat principle, all data – and
therefore all pregnancies – were used in the analyses.
Results
Baseline characteristics and subject disposition
A total of 470 subjects were randomized, of whom 313 were
pregnant during the trial and 157 were not pregnant during the
trial. Of the 313 pregnant subjects, 310 were exposed to the
trial treatment and were pregnant during the trial (n¼ 152
IDet; n¼ 158 NPH) (Supplementary Figure 1). The majority
of the 157 non-pregnant subjects were withdrawn because
they met the withdrawal criteria of failure to reach A1C
8.0% [64 mmol/mol] after 9 months (n¼ 14 IDet; n¼ 10
NPH) or failure to conceive within 12 months of randomiza-
tion (n¼ 44 IDet; n¼ 32 NPH). The total number of
pregnancies reported for this trial was 312 (n¼ 152 IDet;
n¼ 160 NPH) due to two subjects in the NPH group having
miscarriages, but remaining in the trial and becoming
pregnant again. In accordance with the intention-to-treat
principle, all data – and therefore all pregnancies – were used
in the analyses.
Baseline subject characteristics are shown in
Supplementary Table 1. The baseline characteristics were
similar between both treatment groups. The mode of delivery
is shown in Supplementary Table 2.
Perinatal outcomes
Of the total number of pregnancies, the composite pregnancy
outcome was experienced by 62.7% (n¼ 89) of IDet and
66.2% (n¼ 96) of NPH-treated pregnancies (odds ratio IDet/
NPH 0.86 [95% CI 0.53;1.40], not significant) (Table 1).
Pregnancy outcomes for liveborn children are detailed in
Table 1. GA at delivery was significantly greater for offspring
in the IDet treatment arm compared with those in the NPH
treatment arm (mean [SD] IDet: 38.2 [1.9] weeks; NPH: 37.8
[1.5] weeks; mean treatment difference IDet/NPH 0.49 weeks
Table 1. Fetal and perinatal outcomes.
IDet NPH
Odds ratio [95% CI] p Value
n % n %
Number of subjects 152 – 158 – – –
Number of pregnancies 152 – 160 – – –
Pregnancy outcome at follow-up 142 145 – –
Live birthsz 128 90.1 136* 93.8 0.61 [0.25;1.50] p¼ 0.284
Early fetal deathz 11 7.7 9 6.2 – –
Spontaneous abortion 10 7.0 8 5.5 – –
Ectopic pregnancy 1 0.7 1 0.7 – –
Induced abortionz 1 0.7 0 0.0 – –
Perinatal deathz 2 1.4 1 0.7 – –
Neonatal deathz 0 0.0 0 0.0 – –
Composite outcome: at least one issue presentz 89 62.7 96 66.2 0.86 [0.53;1.40] p¼ 0.551
Preterm delivery (537 weeks) 26 20.3 36 26.5 0.71 [0.40;1.26] p¼ 0.238
Smally for GA (510th percentile) 3 2.3 1 0.7 – –
Largey for GA (490th percentile) 59 46.1 73 53.7 0.74 [0.46;1.21] p¼ 0.228
Macrosomia (44000 g) 24 18.8 35 25.7 0.67 [0.37;1.20] p¼ 0.180
Neonatal hypoglycemia524 hours post-delivery 15 11.7 24 17.6 0.65 [0.32;1.30] p¼ 0.223
IDet NPH Treatment difference [95% CI] p Value
Mean SD Mean SD
Birth weight (g)x 3504 645 3571 601 41.8 [–191.0;107.1] p¼ 0.581
GA at delivery (weeks)x 38.2 1.9 37.8 1.5 0.49 [0.11;0.88] p¼ 0.012
*There is 1 less live child at follow-up compared with live births as 1 liveborn child died shortly after birth (classified as a perinatal death); yRefers to
body weight; zPercentage of pregnancy outcomes at follow-up; Percentage of live births; xAnalyses based on live births.
GA, gestational age; g, grams; IDet, insulin detemir; NPH, neutral protamine Hagedorn.
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[95% CI 0.11;0.88], p¼ 0.012). There were no other statis-
tically significant differences between the two treatment
groups.
Fetal and perinatal mortality were similar between treat-
ment groups (Table 1). The only induced abortion reported
was in the IDet treatment group, and was due to social
circumstances.
Congenital malformations were classified by two special-
ists as detailed in Table 2 and evaluated by randomized
treatment (Table 3). Furthermore, as congenital malforma-
tions develop during early pregnancy, their frequency by
insulin treatment during organogenesis is also presented
(post hoc analysis) (Table 3). Both of these approaches
showed a similar frequency of malformations for both
treatments. In the first classification by randomized treatment
among women who gave birth or terminated their pregnancy
during the trial, a total of 16 children were recorded as
having one or more malformations (IDet: n¼ 8/142, 5.6%;
NPH: n¼ 8/145, 5.5%). Of these, 10 children had minor
malformations (IDet: n¼ 3/142, 2.1%; NPH: n¼ 7/145, 4.8%)
and 6 children had major malformations (IDet: n¼ 5/142,
3.5%; NPH: n¼ 1/145, 0.7%). Among the women who were
pregnant at withdrawal, we are aware of only one child with a
malformation, classified as a major malformation. Major
malformations were related to the renal system, the central
nervous system, a hip dysplasia and a cleft lip. Only minor
discrepancies between the two specialists’ classifications
were seen, the key differences being the classification of atrial
Table 2. Congenital malformations as diagnosed by two independent experts.









Hip dysplasia IDet Major (reclassified to
minor due to
FU information)
Not a congenital malformation
(developmental disorder
that disappears)
Cleft lip NPH Major Major
IDet (n¼ 79) Meningomyelocele NPH Major Major
Atrial septal defect
Hemangioma congenital
NPH Both minor Both major
Hemangioma congenital
(diagnosed after the EOT)
NPH Minor Not a congenital malformation
Dandy–Walker syndrome
Pulmonary hypoplasia
NPH Both major Both major
Polydactyly Insulin glargine Minor Minor
NPH (n¼ 83) Cardiac hypertrophy
Patent ductus arteriosus
NPH Both minor Not congenital malformations
(FU: patent ductus
arteriosus was minor
and did not require surgery)
Atrial septal defect NPH Minor Not a congenital malformation






IDet All major All major
IDet (n¼ 73) Hydronephrosis IDet Major Major
Heart disease congenital IDet Minor Not a congenital malformation.
Transient minor anomaly
NPH (n¼ 75) Heart disease congenital NPH Minor Not a congenital malformation.
Transient minor anomaly
Congenital laryngeal stridor NPH Minor Not a congenital malformation
Atrial septal defect NPH Minor Major
Ventricular septal defect NPH Minor Major
Pelvic kidney* (diagnosed after
mother was withdrawn while
pregnant due to A1C48%
[464 mmol/mol] at confirmation
of pregnancy
NPH Major Major
*This malformation from a woman withdrawn from the study is not included in the trial database or further calculations.
Follow-up was from birth until 6 weeks after birth.
A1C, glycated hemoglobin; EOT, end of trial; FU, follow-up; IDet, insulin detemir; MedDRA, Medical Dictionary for Regulatory Activities; NPH,
neutral protamine Hagedorn.
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septal defect and ventricular septal defect in the NPH
(pregnant after randomization) group and hip dysplasia in
the IDet (pregnant at randomization) group.
Adverse events
Adverse events in children were recorded during the entire
trial period and covered both fetuses and newborn children up
to the age of 6 weeks (Supplementary Tables 3 and 4). There
was no difference in the incidence of AEs in the offspring
between the treatment groups (IDet: 37%; NPH: 35%) or in
the number of AEs per child (IDet: 2.2; NPH: 2.7)
(Supplementary Table 3). There was no difference between
the treatment groups in the incidence of severe AEs. Only one
AE (fetal distress syndrome), which was in the IDet group,
was considered by the investigator to be possibly or probably
related to both the basal and bolus insulins (Supplementary
Table 3). Serious AEs occurred in slightly more children in
the IDet group (23.7%) than in the NPH group (20.3%).
Pregnancy, puerperium and perinatal AE profiles for pregnant
women were similar between the two groups, and did not
exceed that expected in pregnancy complicated by diabetes;
for example, 16 (10.5%) women in the IDet group and 11
(7.0%) women in the NPH group experienced preeclampsia
(not statistically significant).
Discussion
This is the first randomized controlled trial of a basal insulin
analog in pregnant women with type 1 diabetes. This study
demonstrates that IDet is as well tolerated as NPH with
respect to perinatal morbidity and mortality, and no specific
safety issues were identified. The overall numbers of AEs in
the offspring were similar for both treatment groups, although
a numerically higher frequency of serious AEs in the
offspring was seen for IDet compared with NPH. In addition,
the frequency of malformations was similar for IDet
compared with NPH, regardless of whether the malformations
were evaluated by randomized treatment or treatment during
organogenesis.
The maternal outcomes of this trial have been reported in
detail separately, but the overall findings indicated that
treatment with IDet resulted in significantly lower fasting PG,
and comparable A1C levels and hypoglycemia incidence
compared with NPH [16]. Previous studies were small and
retrospective, and focused on treatment with either insulin
glargine or NPH [15]. The present trial included a large
number of subjects in a challenging population. The trial was
powered to show non-inferiority for IDet compared with NPH
with regards to efficacy late in pregnancy. It is of note,
however, that to power a trial to detect uncommon perinatal
outcomes would always require a much larger sample size. In
light of this, long-term observational databases would be the
most appropriate method to complement the safety data from
randomized controlled trials, and collection of such data is
currently in progress.
There are no direct data with which to compare our trial
[15]. One other randomized controlled trial compared IAsp
with soluble human insulin, both used in combination with
NPH, in pregnant women with type 1 diabetes [14,25].
Compared with this trial, perinatal outcomes, including live
births and fetal losses, were similar to the results presented
here. In addition, the number of serious AEs in children was
numerically lower in our trial compared with the IAsp trial
[25]. The incidence of perinatal deaths in our trial (IDet: 14
per 1000 births; NPH: 7 per 1000 births) was lower than
previously reported incidences for pregnancies complicated
by diabetes (23–28 per 1000 births) [26,27].
The frequency of malformations with either IDet or NPH
in this trial was similar regardless of randomization, treatment
during organogenesis or assessment by two independent
specialists. While there were certain differences between the
two specialists’ classifications, these differences reflect the
complexities and subtleties that exist in diagnosing congenital
malformations, and some degree of variation between the
specialists is to be expected [28]. In addition, the results from
Table 3. Summary of congenital malformations by randomized treatment and treatment during organogenesis for children delivered during the trial.
Group Expert 1 classification Expert 2 (blinded post hoc) classification
Randomized treatment IDet (n¼ 142) NPH (n¼ 145) IDet (n¼ 142) NPH (n¼ 145)
n % n % n % n %
Children with congenital malformations 8 5.6 8* 5.5 5 3.5 4* 2.8
Minor 3 2.1 7 4.8 0 0.0 1 0.7
Major 5 3.5 1 0.7 5 3.5 3 2.1
Treatment during organogenesisy IDet (n¼ 84) NPH (n¼ 154) IDet (n¼ 84) NPH (n¼ 154)
n % n % n % n %
Children with congenital malformations 4 4.8 11 7.1 2 2.4 6 3.9
Minor 1 1.2 8 5.2 0 0.0 0 0.0
Major 3 3.6 3 1.9 2 2.4 6 3.9
*There was one additional malformation (preferred term: pelvic kidney; treatment during organogenesis: NPH; randomized treatment: NPH;
classification: major), that was diagnosed after the mother was withdrawn from the trial (detail in Table 2). As this table is based only on those women
who gave birth during the trial, this malformation is not included.
yThose subjects treated with a basal insulin other than IDet or NPH (n¼ 35) or who were unclassifiable (n¼ 14; i.e. used more than one basal insulin or
had missing information about their basal insulin) were not included in the treatment during organogenesis calculations. The woman treated with
insulin glargine during organogenesis (detail in Table 2) is not included.
IDet, insulin detemir; NPH, neutral protamine Hagedorn.
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both specialists may provide further insights into the classi-
fication of congenital malformations.
While a strict A1C inclusion criteria (58% at confirmation
of pregnancy) was used in the present trial, IDet has been
shown in previous studies to have a consistent glucose-
lowering effect and one that was similar in magnitude to that
seen with NPH insulin in non-pregnant subjects with type 1 or
type 2 diabetes [13,19–24]. Therefore, based on the evidence
provided by these previously published studies, we would not
expect there to be any differences between IDet and NPH
insulin in women with a high A1C with respect to perinatal
outcomes.
Both in the rapid-acting analog IAsp study [25] and the
present long-acting analog IDet study, the use of analogs was
associated with a tendency towards pregnancy reaching closer
to term. One could speculate whether a slightly more
appropriate growth of the fetus, although not significantly,
contributed to this.
At the time of the initial IAsp trial, pretrial use of insulin
analogs was approximately 48% [25]. By the recruitment
stage for the current trial, the use of bolus and basal insulin
analogs in pregnancy had increased to approximately 90% and
47%, respectively [15]. This trend may reflect an improved
perception of insulin analog safety in pregnancy, particularly
following the change in the US Food and Drug
Administration (FDA) categorization of IAsp from category
C to category B. Therefore, our trial, the first randomized
controlled trial of a basal insulin analog in pregnant women,
could, in a similar manner, alter prescribing habits, especially
following the update to the US and European labeling for the
use of IDet in pregnant women, with IDet now also being
classified as category B by the FDA following this trial
[29,30].
In conclusion, this randomized controlled trial has shown
that IDet is well tolerated without any specific safety concerns
in pregnant women with type 1 diabetes. These data should
help reassure clinicians in their choice of basal insulin during
pregnancy. Further reassurance will be provided with the
collection of long-term observational data from a large cohort
of mothers and their infants treated with different glucose-
lowering drugs during intra-uterine life.
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